LIQUIDIA CORP
LQDANASDAQTrading Snapshot
- Day Range
- $44.41 – $47.20
- 52-Week Range
- $22.05 – $93.61
- Volume (shares)
- 2,582,539
- Avg Volume (shares)
- —
- Shares Outstanding
- 89.5M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- $158M
- Last Q Revenue
- $172M
- P/E Ratio
- 29.3
- P/S Ratio
- 9.0x
- EPS (TTM)
- $1.39
- Dividend Yield
- —
- Dilution (1yr)
- +18.1%
LIQUIDIA CORP
LQDA
StockOtter · stockotter.spaceAbout LIQUIDIA CORP
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?
LQDA's Q3 results will spotlight the impact of its legal settlement with UTHR, cash flow pressures, profitability prospects and pipeline progress.
Liquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy?
Liquidia Corporation (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Liquidia Corporation Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money on Your LQDA Investments
New York, New York--(Newsfile Corp. - October 21, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of Liquidia Corporation ("Liquidia" or the "Company") (NASDAQ: LQDA) investors concernin
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
Liquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
Liquidia shares surge 25% as settlement ends United Therapeutics litigation
Liquidia Corporation (NASDAQ:LQDA), the biopharmaceutical company, surged 25% to $33.47 after settling all six pending lawsuits with United Therapeutics Corporation (NASDAQ:UTHR), ending years of patent and antitrust dis
United Therapeutics and Liquidia Just Ended Their Patent War. Liquidia Stock Popped 42%
A patent court ruling wiped out nearly half of Liquidia's stock value in a single day, and the settlement that followed cost the company almost every dollar it had in the bank.